BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fisman D, Agrawal D, Leder K. The Effect of Age on Immunologic Response to Recombinant Hepatitis B Vaccine: A Meta‐analysis. CLIN INFECT DIS 2002;35:1368-75. [DOI: 10.1086/344271] [Cited by in Crossref: 122] [Cited by in F6Publishing: 117] [Article Influence: 6.1] [Reference Citation Analysis]
Number Citing Articles
1 Reed SG, Carter D, Casper C, Duthie MS, Fox CB. Correlates of GLA family adjuvants' activities. Semin Immunol 2018;39:22-9. [PMID: 30366662 DOI: 10.1016/j.smim.2018.10.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
2 . Anti-aging medicine literaturewatch. J Anti Aging Med 2003;6:45-64. [PMID: 12971397 DOI: 10.1089/109454503765361588] [Reference Citation Analysis]
3 Kennedy LB, Li Z, Savani BN, Ljungman P. Measuring Immune Response to Commonly Used Vaccinations in Adult Recipients of Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation 2017;23:1614-21. [DOI: 10.1016/j.bbmt.2017.06.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
4 La Fauci V, Riso R, Facciolà A, Ceccio C, Lo Giudice D, Calimeri S, Squeri R. Response to anti-HBV vaccine and 10-year follow-up of antibody levels in healthcare workers. Public Health 2016;139:198-202. [PMID: 27600791 DOI: 10.1016/j.puhe.2016.08.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
5 Hyer RN, Janssen RS. Immunogenicity and safety of a 2-dose hepatitis B vaccine, HBsAg/CpG 1018, in persons with diabetes mellitus aged 60-70 years. Vaccine 2019;37:5854-61. [PMID: 31431412 DOI: 10.1016/j.vaccine.2019.08.005] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
6 Labriola L, Jadoul M. The decades-long fight against HBV transmission to dialysis patients: slow but definite progress. Nephrology Dialysis Transplantation 2010;25:2047-9. [DOI: 10.1093/ndt/gfq238] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
7 Pratt PK Jr, Nunes D, Long MT, Farraye FA. Improved Antibody Response to Three Additional Hepatitis B Vaccine Doses Following Primary Vaccination Failure in Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2019;64:2031-2038. [PMID: 30945037 DOI: 10.1007/s10620-019-05595-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
8 Petry A, Kupek EJ. [Effectiveness of recombinant DNA vaccines against hepatitis B in blood donors in an endemic region of South Brazil]. Rev Soc Bras Med Trop. 2006;39:462-466. [PMID: 17160324 DOI: 10.1590/s0037-86822006000500008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
9 Slike BM, Creegan M, Marovich M, Ngauy V. Humoral Immunity to Primary Smallpox Vaccination: Impact of Childhood versus Adult Immunization on Vaccinia Vector Vaccine Development in Military Populations. PLoS One 2017;12:e0169247. [PMID: 28046039 DOI: 10.1371/journal.pone.0169247] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
10 Dauner A, Agrawal P, Salvatico J, Tapia T, Dhir V, Shaik SF, Drake DR 3rd, Byers AM. The in vitro MIMIC® platform reflects age-associated changes in immunological responses after influenza vaccination. Vaccine 2017;35:5487-94. [PMID: 28413134 DOI: 10.1016/j.vaccine.2017.03.099] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
11 McNulty CA, Bowen JK, Williams AJ. Hepatitis B vaccination in predialysis chronic renal failure patients a comparison of two vaccination schedules. Vaccine 2005;23:4142-7. [PMID: 15913854 DOI: 10.1016/j.vaccine.2005.03.020] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 1.7] [Reference Citation Analysis]
12 Oliveira LC, Silva TE, Alves MH. [Response to hepatitis B vaccine in alcoholics without clinically evident liver cirrhosis]. Arq Gastroenterol 2007;44:195-200. [PMID: 18060270 DOI: 10.1590/s0004-28032007000300003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Weinberger B. Vaccines for the elderly: current use and future challenges. Immun Ageing 2018;15:3. [PMID: 29387135 DOI: 10.1186/s12979-017-0107-2] [Cited by in Crossref: 67] [Cited by in F6Publishing: 58] [Article Influence: 16.8] [Reference Citation Analysis]
14 Raven SFH, Hoebe CJPA, Vossen ACTM, Visser LG, Hautvast JLA, Roukens AHE, van Steenbergen JE. Serological response to three alternative series of hepatitis B revaccination (Fendrix, Twinrix, and HBVaxPro-40) in healthy non-responders: a multicentre, open-label, randomised, controlled, superiority trial. Lancet Infect Dis. 2020;20:92-101. [PMID: 31629649 DOI: 10.1016/s1473-3099(19)30417-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
15 Jackson S, Lentino J, Kopp J, Murray L, Ellison W, Rhee M, Shockey G, Akella L, Erby K, Heyward WL, Janssen RS; HBV-23 Study Group. Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults. Vaccine 2018;36:668-74. [PMID: 29289383 DOI: 10.1016/j.vaccine.2017.12.038] [Cited by in Crossref: 79] [Cited by in F6Publishing: 71] [Article Influence: 15.8] [Reference Citation Analysis]
16 Wang L, Cao D, Wang L, Zhao J, Nguyen LN, Dang X, Ji Y, Wu XY, Morrison ZD, Xie Q, El Gazzar M, Ning S, Moorman JP, Yao ZQ. HCV-associated exosomes promote myeloid-derived suppressor cell expansion via inhibiting miR-124 to regulate T follicular cell differentiation and function. Cell Discov 2018;4:51. [PMID: 30210805 DOI: 10.1038/s41421-018-0052-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
17 Locquet C, Marande JL, Choudat D, Vidal-Trecan G. Hepatitis B vaccination in women healthcare workers: a seroepidemiological survey. Eur J Epidemiol 2007;22:113-9. [PMID: 17295098 DOI: 10.1007/s10654-006-9094-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
18 Meidani M, Khorvash F, Hemati S, Ashrafi F, Ataei B, Daneshmand D. The Immune Response of Vaccination Against Hepatitis B virus in Iranian Patients Undergoing Chemotherapy. Adv Biomed Res 2017;6:88. [PMID: 28828339 DOI: 10.4103/abr.abr_330_13] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
19 Kamath GR, Shah DP, Hwang L. Immune response to hepatitis B vaccination in drug using populations: A systematic review and meta-regression analysis. Vaccine 2014;32:2265-74. [DOI: 10.1016/j.vaccine.2014.02.072] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
20 Weinberger B, Grubeck-Loebenstein B. Vaccines for the elderly. Clin Microbiol Infect 2012;18 Suppl 5:100-8. [PMID: 22862783 DOI: 10.1111/j.1469-0691.2012.03944.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 5.2] [Reference Citation Analysis]
21 Tohme RA, Awosika-Olumo D, Nielsen C, Khuwaja S, Scott J, Xing J, Drobeniuc J, Hu DJ, Turner C, Wafeeg T, Sharapov U, Spradling PR. Evaluation of hepatitis B vaccine immunogenicity among older adults during an outbreak response in assisted living facilities. Vaccine 2011;29:9316-20. [PMID: 22015390 DOI: 10.1016/j.vaccine.2011.10.011] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
22 Höhler T, Groeger-Bicanic G, Hoet B, Stoffel M. Antibody persistence and immune memory elicited by combined hepatitis A and B vaccination in older adults. Vaccine 2007;25:1503-8. [PMID: 17097774 DOI: 10.1016/j.vaccine.2006.10.024] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
23 High K. Immunizations in older adults. Clin Geriatr Med 2007;23:669-85, viii-ix. [PMID: 17631240 DOI: 10.1016/j.cger.2007.03.007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
24 Grosso G, Mistretta A, Marventano S, Ferranti R, Mauro L, Cunsolo R, Proietti L, Malaguarnera M. Long-term persistence of seroprotection by hepatitis B vaccination in healthcare workers of southern Italy. Hepat Mon. 2012;12:e6025. [PMID: 23087756 DOI: 10.5812/hepatmon.6025] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
25 Loustaud-Ratti V, Jacques J, Debette-Gratien M, Carrier P. Hepatitis B and elders: An underestimated issue. Hepatol Res. 2016;46:22-28. [PMID: 25651806 DOI: 10.1111/hepr.12499] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
26 Fisman D, Patrozou E, Carmeli Y, Perencevich E, Tuite AR, Mermel LA; Geographical Variability of Bacteremia Study Group. Geographical variability in the likelihood of bloodstream infections due to gram-negative bacteria: correlation with proximity to the equator and health care expenditure. PLoS One 2014;9:e114548. [PMID: 25521300 DOI: 10.1371/journal.pone.0114548] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
27 Yao ZQ, Moorman JP. Immune exhaustion and immune senescence: two distinct pathways for HBV vaccine failure during HCV and/or HIV infection. Arch Immunol Ther Exp (Warsz). 2013;61:193-201. [PMID: 23400275 DOI: 10.1007/s00005-013-0219-0] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
28 [DOI: 10.1101/2021.02.08.21251325] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
29 Kim JH, Psevdos G Jr, Groce V, Sharp V. Persistence of Protective Hepatitis B Surface Antibody Titers after Successful Double-Dose Hepatitis B Virus Rescue Vaccination in HIV-Infected Patients. Gut Liver 2012;6:86-91. [PMID: 22375176 DOI: 10.5009/gnl.2012.6.1.86] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
30 Chonwattana W, Raengsakulrach B, Holtz TH, Wasinrapee P, Tongtoyai J, Chaikummao S, Pattanasin S, McNicholl JM, van Griensven F, Curlin ME. Hepatitis B vaccination uptake and correlates of serologic response among HIV-infected and uninfected men who have sex with men (MSM) in Bangkok, Thailand. Vaccine. 2016;34:2044-2050. [PMID: 26685092 DOI: 10.1016/j.vaccine.2015.11.071] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
31 Han B, Liu W, Du J, Liu H, Zhao T, Yang S, Wang S, Zhang S, Liu B, Liu Y, Cui F. 12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial. Vaccines (Basel) 2021;9:1407. [PMID: 34960153 DOI: 10.3390/vaccines9121407] [Reference Citation Analysis]
32 Hirst A, Hyer RN, Janssen RS. Comparative cost-effectiveness of a 2-dose versus 3-dose vaccine for hepatitis B prevention in selected adult populations. Vaccine 2021;39:4733-41. [PMID: 34030898 DOI: 10.1016/j.vaccine.2021.05.020] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Reens AL, Cabral DJ, Liang X, Norton JE Jr, Therien AG, Hazuda DJ, Swaminathan G. Immunomodulation by the Commensal Microbiome During Immune-Targeted Interventions: Focus on Cancer Immune Checkpoint Inhibitor Therapy and Vaccination. Front Immunol 2021;12:643255. [PMID: 34054810 DOI: 10.3389/fimmu.2021.643255] [Reference Citation Analysis]
34 Martins RM, Bensabath G, Arraes LC, Oliveira Mde L, Miguel JC, Barbosa GG, Camacho LA. Multicenter study on the immunogenicity and safety of two recombinant vaccines against hepatitis B. Mem Inst Oswaldo Cruz 2004;99:865-71. [PMID: 15761604 DOI: 10.1590/s0074-02762004000800014] [Cited by in Crossref: 21] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
35 Kundi M. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Review of Vaccines 2014;6:133-40. [DOI: 10.1586/14760584.6.2.133] [Cited by in Crossref: 128] [Cited by in F6Publishing: 115] [Article Influence: 16.0] [Reference Citation Analysis]
36 Li F, Cheng L, Murphy CM, Reszka-Blanco NJ, Wu Y, Chi L, Hu J, Su L. Minicircle HBV cccDNA with a Gaussia luciferase reporter for investigating HBV cccDNA biology and developing cccDNA-targeting drugs. Sci Rep 2016;6:36483. [PMID: 27819342 DOI: 10.1038/srep36483] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
37 Sanadgol H. Levamisole usage as an adjuvant to hepatitis B vaccine in hemodialysis patients, yes or no? Nephrourol Mon 2013;5:673-8. [PMID: 23577329 DOI: 10.5812/numonthly.3985] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
38 Yağcı M, Acar K, Sucak GT, Yamaç K, Haznedar R. Hepatitis B virus vaccine in lymphoproliferative disorders: a prospective randomized study evaluating the efficacy of granulocyte-macrophage colony stimulating factor as a vaccine adjuvant. Eur J Haematol 2007;79:292-6. [DOI: 10.1111/j.1600-0609.2007.00912.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
39 Schwarz T, Tober-Lau P, Hillus D, Helbig ET, Lippert LJ, Thibeault C, Koch W, Landgraf I, Michel J, Bergfeld L, Niemeyer D, Mühlemann B, Conrad C, Dang-Heine C, Kasper S, Münn F, Kappert K, Nitsche A, Tauber R, Schmidt S, Kopankiewicz P, Bias H, Seybold J, von Kalle C, Jones TC, Suttorp N, Drosten C, Sander LE, Corman VM, Kurth F. Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany. Emerg Infect Dis 2021;27:2174-8. [PMID: 34102097 DOI: 10.3201/eid2708.211145] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
40 Whitaker JA, Rouphael NG, Edupuganti S, Lai L, Mulligan MJ. Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1. Lancet Infect Dis. 2012;12:966-976. [PMID: 23174382 DOI: 10.1016/s1473-3099(12)70243-8] [Cited by in Crossref: 44] [Cited by in F6Publishing: 23] [Article Influence: 4.9] [Reference Citation Analysis]
41 Heyward WL, Kyle M, Blumenau J, Davis M, Reisinger K, Kabongo ML, Bennett S, Janssen RS, Namini H, Martin JT. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age. Vaccine. 2013;31:5300-5305. [PMID: 23727002 DOI: 10.1016/j.vaccine.2013.05.068] [Cited by in Crossref: 67] [Cited by in F6Publishing: 60] [Article Influence: 7.4] [Reference Citation Analysis]
42 McClean KL; approved by CATMAT. Statement on Older Travellers: Committee to Advise on Tropical Medicine and Travel. Can Commun Dis Rep 2011;37:1-24. [PMID: 31692635 DOI: 10.14745/ccdr.v37i00a02] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
43 Vesikari T, Finn A, van Damme P, Leroux-Roels I, Leroux-Roels G, Segall N, Toma A, Vallieres G, Aronson R, Reich D, Arora S, Ruane PJ, Cone CL, Manns M, Cosgrove C, Faust SN, Ramasamy MN, Machluf N, Spaans JN, Yassin-Rajkumar B, Anderson D, Popovic V, Diaz-Mitoma F; CONSTANT Study Group. Immunogenicity and Safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine: A Phase 3 Randomized Clinical Trial. JAMA Netw Open 2021;4:e2128652. [PMID: 34636914 DOI: 10.1001/jamanetworkopen.2021.28652] [Reference Citation Analysis]
44 Yang L, Yao J, Li J, Chen Y, Jiang ZG, Ren JJ, Xu KJ, Ruan B, Yang SG, Wang B, Xie TS, Li Q. Suitable hepatitis B vaccine for adult immunization in China. Immunol Res 2016;64:242-50. [PMID: 26645972 DOI: 10.1007/s12026-015-8742-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
45 Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Perona P, Poncelet S, Zahaf T, Hardt K, Descamps D, Dubin G; HPV Study Group for Adult Women. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 2009;27:581-7. [PMID: 19022320 DOI: 10.1016/j.vaccine.2008.10.088] [Cited by in Crossref: 106] [Cited by in F6Publishing: 95] [Article Influence: 7.6] [Reference Citation Analysis]
46 Edelman R, Deming ME, Toapanta FR, Heuser MD, Chrisley L, Barnes RS, Wasserman SS, Blackwelder WC, Handwerger BS, Pasetti M, Siddiqui KM, Sztein MB. The SENIEUR protocol and the efficacy of hepatitis B vaccination in healthy elderly persons by age, gender, and vaccine route. Immun Ageing 2020;17:9. [PMID: 32355503 DOI: 10.1186/s12979-020-00179-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
47 Hakim FT, Flomerfelt FA, Boyiadzis M, Gress RE. Aging, immunity and cancer. Current Opinion in Immunology 2004;16:151-6. [DOI: 10.1016/j.coi.2004.01.009] [Cited by in Crossref: 104] [Cited by in F6Publishing: 83] [Article Influence: 5.8] [Reference Citation Analysis]
48 Sadlier C, Madden K, O'Gorman S, Crowley B, Bergin C. Development of chronic hepatitis B infection in a hepatitis B vaccine responder. Int J STD AIDS 2017;28:526-8. [PMID: 28266264 DOI: 10.1177/0956462416674835] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
49 Ahishali E, Boztas G, Akyuz F, Ibrisim D, Poturoglu S, Pinarbasi B, Ozdil S, Mungan Z. Response to hepatitis B vaccination in patients with celiac disease. Dig Dis Sci. 2008;53:2156-2159. [PMID: 18157638 DOI: 10.1007/s10620-007-0128-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 2.2] [Reference Citation Analysis]
50 Chen WH, Kozlovsky BF, Effros RB, Grubeck-Loebenstein B, Edelman R, Sztein MB. Vaccination in the elderly: an immunological perspective. Trends Immunol 2009;30:351-9. [PMID: 19540808 DOI: 10.1016/j.it.2009.05.002] [Cited by in Crossref: 155] [Cited by in F6Publishing: 140] [Article Influence: 11.9] [Reference Citation Analysis]
51 Shim J, Kim KY, Kim BH, Chun H, Lee MS, Hwangbo Y, Jang JY, Dong SH, Kim HJ, Chang YW. Anti-hepatitis B core antibody is not required for prevaccination screening in healthcare workers. Vaccine. 2011;29:1721-1726. [PMID: 21147128 DOI: 10.1016/j.vaccine.2010.11.044] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
52 Rossman H, Shilo S, Meir T, Gorfine M, Shalit U, Segal E. COVID-19 dynamics after a national immunization program in Israel. Nat Med 2021;27:1055-61. [PMID: 33875890 DOI: 10.1038/s41591-021-01337-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 32.0] [Reference Citation Analysis]
53 Schwarz TF, Huang LM, Lin TY, Wittermann C, Panzer F, Valencia A, Suryakiran PV, Lin L, Descamps D. Long-term immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in 10- to 14-year-old girls: open 6-year follow-up of an initial observer-blinded, randomized trial. Pediatr Infect Dis J 2014;33:1255-61. [PMID: 24978856 DOI: 10.1097/INF.0000000000000460] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
54 Vermeiren AP, Hoebe CJ, Dukers-Muijrers NH. High non-responsiveness of males and the elderly to standard hepatitis B vaccination among a large cohort of healthy employees. J Clin Virol. 2013;58:262-264. [PMID: 23895931 DOI: 10.1016/j.jcv.2013.07.003] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 4.9] [Reference Citation Analysis]
55 Kim HN, Harrington RD, Van Rompaey SE, Kitahata MM. Independent clinical predictors of impaired response to hepatitis B vaccination in HIV-infected persons. Int J STD AIDS. 2008;19:600-604. [PMID: 18725550 DOI: 10.1258/ijsa.2007.007197] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 2.9] [Reference Citation Analysis]
56 Janssen JM, Jackson S, Heyward WL, Janssen RS. Immunogenicity of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in subpopulations of healthy adults 18-70 years of age. Vaccine 2015;33:3614-8. [PMID: 26067185 DOI: 10.1016/j.vaccine.2015.05.070] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
57 Pondé RADA. Expression and detection of anti-HBs antibodies after hepatitis B virus infection or vaccination in the context of protective immunity. Arch Virol 2019;164:2645-58. [DOI: 10.1007/s00705-019-04369-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
58 Cruciani M, Mengoli C, Serpelloni G, Mazzi R, Bosco O, Malena M. Granulocyte macrophage colony-stimulating factor as an adjuvant for hepatitis B vaccination: A meta-analysis. Vaccine 2007;25:709-18. [DOI: 10.1016/j.vaccine.2006.08.015] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 2.0] [Reference Citation Analysis]
59 Cossio-gil Y, Martínez-gómez X, Campins-martí M, Rodrigo-pendás JÁ, Borruel-sainz N, Rodríguez-frías F, Casellas-jordà F. Immunogenicity of hepatitis B vaccine in patients with inflammatory bowel disease and the benefits of revaccination: Hepatitis B vaccine in bowel disease. J Gastroenterol Hepatol 2015;30:92-8. [DOI: 10.1111/jgh.12712] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
60 Liu J, Qiu S, Lu J, Yan B, Feng Y, Li L, Zhang G, Wang F, He P, Fang X, Hu Z, Liang X, Xu A, Zhang L. Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-Treatment Patients With Chronic Hepatitis C: An Open-Label Control Study in China. J Infect Dis 2017;216:327-35. [PMID: 28859430 DOI: 10.1093/infdis/jix295] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
61 Kirkpatrick BD, Alston WK. Current immunizations for travel: . Current Opinion in Infectious Diseases 2003;16:369-74. [DOI: 10.1097/00001432-200310000-00001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
62 Sekiba K, Otsuka M, Ohno M, Yamagami M, Kishikawa T, Suzuki T, Ishibashi R, Seimiya T, Tanaka E, Koike K. Hepatitis B virus pathogenesis: Fresh insights into hepatitis B virus RNA. World J Gastroenterol 2018; 24(21): 2261-2268 [PMID: 29881235 DOI: 10.3748/wjg.v24.i21.2261] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
63 Tejada-Pérez JJ, Vázquez-Vicente JJ, Herrera-Burgos MR, Martín-Martín FG, Parrón-Carreño T, Alarcón-Rodríguez R. Fendrix® Vaccine Effectiveness in Healthcare Workers Who Are Non-Responsive to Engerix B® Vaccination. Vaccines (Basel) 2021;9:279. [PMID: 33808589 DOI: 10.3390/vaccines9030279] [Reference Citation Analysis]
64 Sabidó M, Gavaldà L, Olona N, Ramon JM. Timing of hepatitis B vaccination: its effect on vaccine response in health care workers. Vaccine 2007;25:7568-72. [PMID: 17870215 DOI: 10.1016/j.vaccine.2007.08.025] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
65 Park Y, Kim Y, Stanley D. Cellular immunosenescence in adult male crickets, Gryllus assimilis. Arch Insect Biochem Physiol 2011;76:185-94. [PMID: 21254201 DOI: 10.1002/arch.20394] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
66 Tazhibi M, Hajivandi A, Tafti AD, Fallahzadeh H. The efficacy of hepatitis B vaccine in Iranian population: A systematic review and meta-analysis. J Educ Health Promot 2014;3:53. [PMID: 25077146 DOI: 10.4103/2277-9531.134741] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
67 Amanna IJ. Balancing the Efficacy and Safety of Vaccines in the Elderly. Open Longev Sci 2012;6:64-72. [PMID: 23565132 DOI: 10.2174/1876326X01206010064] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
68 Meier MA, Berger CT. A simple clinical score to identify likely hepatitis B vaccination non-responders - data from a retrospective single center study. BMC Infect Dis 2020;20:891. [PMID: 33238923 DOI: 10.1186/s12879-020-05634-y] [Reference Citation Analysis]
69 Tanwar S, Thursz M. Granulocyte colony-stimulating factor as a novel adjunct to improve hepatitis B vaccination. World J Hepatol 2010; 2(3): 136-138 [PMID: 21160984 DOI: 10.4254/wjh.v2.i3.136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
70 Kim HN, Harrington RD, Crane HM, Dhanireddy S, Dellit TH, Spach DH. Hepatitis B vaccination in HIV-infected adults: current evidence, recommendations and practical considerations. Int J STD AIDS. 2009;20:595-600. [PMID: 19710329 DOI: 10.1258/ijsa.2009.009126] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 3.5] [Reference Citation Analysis]
71 Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Schulze K, Poncelet SM, Catteau G, Thomas F, Descamps D. Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years. Hum Vaccin 2011;7:958-65. [PMID: 21892005 DOI: 10.4161/hv.7.9.15999] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
72 Laksananun N, Praparattanapan J, Kotarathititum W, Supparatpinyo K, Chaiwarith R. Immunogenicity and safety of 4 vs. 3 standard doses of HBV vaccination in HIV-infected adults with isolated anti-HBc antibody. AIDS Res Ther 2019;16:10. [PMID: 31053142 DOI: 10.1186/s12981-019-0225-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
73 Denis F. Vaccination contre l'hépatite B. EMC - Hépatologie 2007;2:1-10. [DOI: 10.1016/s1155-1976(07)45904-6] [Reference Citation Analysis]
74 O'Halloran JA, De Gascun CF, Dunford L, Carr MJ, Connell J, Howard R, Hall WW, Lambert JS. Hepatitis B virus vaccine failure resulting in chronic hepatitis B infection. J Clin Virol. 2011;52:151-154. [PMID: 21802353 DOI: 10.1016/j.jcv.2011.06.020] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
75 Kakisaka K, Sakai A, Yoshida Y, Miyasaka A, Takahashi F, Sumazaki R, Takikawa Y. Hepatitis B Surface Antibody Titers at One and Two Years after Hepatitis B Virus Vaccination in Healthy Young Japanese Adults. Intern Med 2019;58:2349-55. [PMID: 31118375 DOI: 10.2169/internalmedicine.2231-18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
76 Conrad A, Perry M, Langlois ME, Labussière-Wallet H, Barraco F, Ducastelle-Leprêtre S, Larcher MV, Balsat M, Boccard M, Chidiac C, Ferry T, Roure-Sobas C, Salles G, Valour F, Ader F; Lyon HemInf Study Group. Efficacy and Safety of Revaccination against Tetanus, Diphtheria, Haemophilus influenzae Type b and Hepatitis B Virus in a Prospective Cohort of Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2020;26:1729-37. [PMID: 32428736 DOI: 10.1016/j.bbmt.2020.05.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
77 Leroux-Roels G. Old and new adjuvants for hepatitis B vaccines. Med Microbiol Immunol 2015;204:69-78. [PMID: 25523196 DOI: 10.1007/s00430-014-0375-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
78 Akache B, Stark FC, Jia Y, Deschatelets L, Dudani R, Harrison BA, Agbayani G, Williams D, Jamshidi MP, Krishnan L, McCluskie MJ. Sulfated archaeol glycolipids: Comparison with other immunological adjuvants in mice. PLoS One 2018;13:e0208067. [PMID: 30513093 DOI: 10.1371/journal.pone.0208067] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
79 Keating GM, Noble S. Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. Drugs. 2003;63:1021-1051. [PMID: 12699402 DOI: 10.2165/00003495-200363100-00006] [Cited by in Crossref: 139] [Cited by in F6Publishing: 130] [Article Influence: 7.3] [Reference Citation Analysis]
80 Weinberger B, Haks MC, de Paus RA, Ottenhoff THM, Bauer T, Grubeck-Loebenstein B. Impaired Immune Response to Primary but Not to Booster Vaccination Against Hepatitis B in Older Adults. Front Immunol 2018;9:1035. [PMID: 29868000 DOI: 10.3389/fimmu.2018.01035] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
81 Albayrak A, Ertek M, Tasyaran MA, Pirim I. Role of HLA allele polymorphism in chronic hepatitis B virus infection and HBV vaccine sensitivity in patients from eastern Turkey. Biochem Genet. 2011;49:258-269. [PMID: 21188498 DOI: 10.1007/s10528-010-9404-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
82 Leder K, Chen L, Wilson M. Aggregate travel vs. single trip assessment: Arguments for cumulative risk analysis. Vaccine 2012;30:2600-4. [DOI: 10.1016/j.vaccine.2011.12.133] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
83 Petäjä T, Pedersen C, Poder A, Strauss G, Catteau G, Thomas F, Lehtinen M, Descamps D. Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women. Int J Cancer 2011;129:2147-57. [DOI: 10.1002/ijc.25887] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 5.5] [Reference Citation Analysis]
84 Tran TQ, Grimes CZ, Lai D, Troisi CL, Hwang LY. Effect of age and frequency of injections on immune response to hepatitis B vaccination in drug users. Vaccine 2012;30:342-9. [PMID: 22075088 DOI: 10.1016/j.vaccine.2011.10.084] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
85 Weinberger B. Vaccination of older adults: Influenza, pneumococcal disease, herpes zoster, COVID-19 and beyond. Immun Ageing 2021;18:38. [PMID: 34627326 DOI: 10.1186/s12979-021-00249-6] [Reference Citation Analysis]
86 Zhang W, Han L, Lin C, Wang H, Pang X, Li L, Gao P, Lin H, Gong X, Tang Y, Ma J, Zhang H, Wang C, Yang P, Li H, Sun M, He X. Surface antibody and cytokine response to recombinant Chinese hamster ovary cell (CHO) hepatitis B vaccine. Vaccine 2011;29:6276-82. [PMID: 21722684 DOI: 10.1016/j.vaccine.2011.06.045] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
87 Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Meta-analysis: the effect of age on immunological response to hepatitis B vaccine in end-stage renal disease. Aliment Pharmacol Ther. 2004;20:1053-1062. [PMID: 15569107 DOI: 10.1111/j.1365-2036.2004.02264.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 3.3] [Reference Citation Analysis]
88 Boot HJ, van der Waaij LA, Schirm J, Kallenberg CG, van Steenbergen J, Wolters B. Acute hepatitis B in a healthcare worker: a case report of genuine vaccination failure. J Hepatol. 2009;50:426-431. [PMID: 19091440 DOI: 10.1016/j.jhep.2008.07.040] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
89 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2006; 14(27): 2713-2717 [DOI: 10.11569/wcjd.v14.i27.2713] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
90 Chang JY, Jung SA, Moon CM, Kim SE, Jung HK, Shim KN. Response to hepatitis B vaccination in patients with inflammatory bowel disease: a prospective observational study in Korea. Intest Res 2018;16:599-608. [PMID: 30301330 DOI: 10.5217/ir.2018.00012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
91 Shi L, Wang JM, Ren JP, Cheng YQ, Ying RS, Wu XY, Lin SM, Griffin JW, Li GY, Moorman JP. KLRG1 impairs CD4+ T cell responses via p16ink4a and p27kip1 pathways: role in hepatitis B vaccine failure in individuals with hepatitis C virus infection. J Immunol. 2014;192:649-657. [PMID: 24337749 DOI: 10.4049/jimmunol.1302069] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
92 Leonardi S, Praticò AD, Lionetti E, Spina M, Vitaliti G, Rosa ML. Intramuscular vs intradermal route for hepatitis B booster vaccine in celiac children. World J Gastroenterol 2012; 18(40): 5729-5733 [PMID: 23155313 DOI: 10.3748/wjg.v18.i40.5729] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
93 Dimitrov Y, Ducher M, Kribs M, Laurent G, Richter S, Fauvel JP. Variables linked to hepatitis B vaccination success in non-dialyzed chronic kidney disease patients: Use of a bayesian model. Nephrol Ther 2019;15:215-9. [PMID: 31129001 DOI: 10.1016/j.nephro.2019.02.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
94 Bruguera M. Prevención de las hepatitis virales. Enfermedades Infecciosas y Microbiología Clínica 2006;24:649-56. [DOI: 10.1157/13095377] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
95 Herrero-Fernández I, Rosado-Sánchez I, Genebat M, Tarancón-Díez L, Rodríguez-Méndez MM, Pozo-Balado MM, Lozano C, Ruiz-Mateos E, Leal M, Pacheco YM. Improved CD4 T cell profile in HIV-infected subjects on maraviroc-containing therapy is associated with better responsiveness to HBV vaccination. J Transl Med 2018;16:238. [PMID: 30157873 DOI: 10.1186/s12967-018-1617-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
96 Grammatikos AP, Mantadakis E, Falagas ME. Meta-analyses on Pediatric Infections and Vaccines. Infectious Disease Clinics of North America 2009;23:431-57. [DOI: 10.1016/j.idc.2009.01.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
97 Kramer ES, Hofmann C, Smith PG, Shiffman ML, Sterling RK. Response to Hepatitis A and B Vaccine Alone or in Combination in Patients with Chronic Hepatitis C Virus and Advanced Fibrosis. Dig Dis Sci 2009;54:2016-25. [DOI: 10.1007/s10620-009-0867-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
98 Esaulenko EV, Yakovlev AA, Volkov GA, Sukhoruk AA, Surkov KG, Kruglyakov PV, Diaz-Mitoma F. Efficacy and Safety of a 3-Antigen (Pre-S1/Pre-S2/S) Hepatitis B Vaccine: Results of a Phase 3 randomized clinical trial in the Russian Federation. Clin Infect Dis 2020:ciaa1649. [PMID: 33119068 DOI: 10.1093/cid/ciaa1649] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
99 Van Damme P, Van Herck K, Van der Wielen M. Combined hepatitis A and B vaccine in elderly. Vaccine 2004;22:303-4. [DOI: 10.1016/j.vaccine.2003.08.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
100 Lebossé F, Zoulim F. [Hepatitis B vaccine and liver cancer]. Bull Cancer 2021;108:90-101. [PMID: 33358507 DOI: 10.1016/j.bulcan.2020.10.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
101 Ertem D, Gonen I, Tanidir C, Ugras M, Yildiz A, Pehlivanoğlu E, Eksioglu-Demiralp E. The response to hepatitis B vaccine: does it differ in celiac disease? Eur J Gastroenterol Hepatol 2010;22:787-93. [PMID: 19584738 DOI: 10.1097/MEG.0b013e32832e9d41] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
102 Van der Wielen M, Van Damme P, Chlibek R, Smetana J, von Sonnenburg F. Hepatitis A/B vaccination of adults over 40 years old: Comparison of three vaccine regimens and effect of influencing factors. Vaccine 2006;24:5509-15. [DOI: 10.1016/j.vaccine.2006.04.016] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 3.9] [Reference Citation Analysis]
103 Raven S, Hautvast J, Steenbergen JV, Akkermans R, Weykamp C, Smits F, Hoebe C, Vossen A. Diagnostic performance of serological assays for anti-HBs testing: Results from a quality assessment program. J Clin Virol 2017;87:17-22. [PMID: 27987422 DOI: 10.1016/j.jcv.2016.12.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
104 Yang S, Tian G, Cui Y, Ding C, Deng M, Yu C, Xu K, Ren J, Yao J, Li Y, Cao Q, Chen P, Xie T, Wang C, Wang B, Mao C, Ruan B, Jiang T, Li L. Factors influencing immunologic response to hepatitis B vaccine in adults. Sci Rep. 2016;6:27251. [PMID: 27324884 DOI: 10.1038/srep27251] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 8.0] [Reference Citation Analysis]
105 Kang S, Kim KH, Kim YT, Kim YT, Kim JH, Song YS, Shin SH, Ryu HS, Han JW, Kang JH, Park SY. Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo-controlled trial in 176 Korean subjects. Int J Gynecol Cancer 2008;18:1013-9. [PMID: 17986242 DOI: 10.1111/j.1525-1438.2007.01123.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
106 Moore SE, Collinson AC, Fulford AJ, Jalil F, Siegrist C, Goldblatt D, Hanson LÅ, Prentice AM. Effect of month of vaccine administration on antibody responses in The Gambia and Pakistan. Trop Med Int Health 2006;11:1529-41. [DOI: 10.1111/j.1365-3156.2006.01700.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 2.3] [Reference Citation Analysis]
107 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2006; 14(27): 2661-2667 [DOI: 10.11569/wcjd.v14.i27.2661] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
108 Leonardi S, Spina M, Spicuzza L, Rotolo N, La Rosa M. Hepatitis B vaccination failure in celiac disease: Is there a need to reassess current immunization strategies? Vaccine 2009;27:6030-3. [DOI: 10.1016/j.vaccine.2009.07.099] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 2.9] [Reference Citation Analysis]
109 Joukar F, Mansour-Ghanaei F, Naghipour MR, Asgharnezhad M. Immune Responses to Single-Dose Versus Double-Dose Hepatitis B Vaccines in Healthcare Workers not Responding to the Primary Vaccine Series: A Randomized Clinical Trial. Hepat Mon 2016;16:e32799. [PMID: 27148385 DOI: 10.5812/hepatmon.32799] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
110 Jackson Y, Chappuis F, Mezger N, Kanappa K, Loutan L. High immunogenicity of delayed third dose of hepatitis B vaccine in travellers. Vaccine. 2007;25:3482-3484. [PMID: 17306910 DOI: 10.1016/j.vaccine.2006.12.053] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
111 Aljaberi N, Ghulam E, Smitherman EA, Favier L, Dykes DMH, Danziger-Isakov LA, Brady RC, Huggins J. Maintaining Hepatitis B Protection in Immunocompromised Pediatric Rheumatology and Inflammatory Bowel Disease Patients. J Rheumatol. 2020;. [PMID: 32739895 DOI: 10.3899/jrheum.200283] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
112 Yao J, Qiu Y, Chen Y, Jiang Z, Shen L, Shan H, Dai X, Li Q, Liu Y, Ren W, Ren J. Optimal vaccination program for healthy adults in China. Hum Vaccin Immunother 2015;11:2389-94. [PMID: 26158622 DOI: 10.1080/21645515.2015.1053674] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
113 Abdoli A, Ardakani HM. Helminth infections and immunosenescence: The friend of my enemy. Exp Gerontol 2020;133:110852. [PMID: 32007545 DOI: 10.1016/j.exger.2020.110852] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
114 Kang JH, Moon JW, Kong SH, Hwang KS, Mok JS, Lee HJ. Comparison of the seroconversion rate after primary hepatitis B vaccination and after revaccination of non-responders in full-term infants according to mother's HBsAg seropositivity. Korean J Pediatr 2008;51:1165. [DOI: 10.3345/kjp.2008.51.11.1165] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
115 Sablan BP, Kim DJ, Barzaga NG, Chow WC, Cho M, Ahn SH, Hwang SG, Lee JH, Namini H, Heyward WL. Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine. Vaccine 2012;30:2689-96. [PMID: 22342916 DOI: 10.1016/j.vaccine.2012.02.001] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 4.4] [Reference Citation Analysis]
116 Schmeink CE, Bekkers RL, Josefsson A, Richardus JH, Berndtsson Blom K, David MP, Dobbelaere K, Descamps D. Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls. Vaccine 2011;29:9276-83. [PMID: 21856349 DOI: 10.1016/j.vaccine.2011.08.037] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
117 Yuan J, Yang Y, Han F, Zhang P, Du XY, Jiang H, Chen JH. Quality control measures for lowering the seroconversion rate of hemodialysis patients with hepatitis B or C virus. Hepatobiliary Pancreat Dis Int 2012;11:302-6. [PMID: 22672825 DOI: 10.1016/s1499-3872(12)60164-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
118 Li X, Xu Y, Dong Y, Yang X, Ye B, Wang Y, Chen Y. Monitoring the efficacy of infant hepatitis B vaccination and revaccination in 0- to 8-year-old children: Protective anti-HBs levels and cellular immune responses. Vaccine 2018;36:2442-9. [PMID: 29588118 DOI: 10.1016/j.vaccine.2018.03.044] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
119 Mena G, Llupià A, García-basteiro AL, Díez C, León A, García F, Bayas JM. Assessing the immunological response to hepatitis B vaccination in HIV-infected patients in clinical practice. Vaccine 2012;30:3703-9. [DOI: 10.1016/j.vaccine.2012.03.018] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
120 Sjogren MH. Prevention of hepatitis B in nonresponders to initial hepatitis B virus vaccination. Am J Med. 2005;118 Suppl 10A:34S-39S. [PMID: 16271539 DOI: 10.1016/j.amjmed.2005.07.012] [Cited by in Crossref: 51] [Cited by in F6Publishing: 55] [Article Influence: 3.0] [Reference Citation Analysis]